In this retrospective study, clinical data were collected from hospitalized patients with lung cancer who reported sleep disturbances. From this dataset, 38 patients who received Suanzaoren decoction as part of their treatment in addition to standard care were compared to 37 patients who only received standard care. Sleep quality was evaluated using a specific sleep quality assessment tool, and fatigue levels were assessed using a cancer fatigue scale. For patients with available data, objective sleep parameters were also tracked using actigraphy monitoring.

The primary findings of the study showed that patients who were administered Suanzaoren decoction had notably lower scores in sleep quality assessment after treatment compared to the control group. Similarly, their fatigue scores were also considerably lower. Actigraphy-informed parameters indicated that total sleep duration and the proportion of deep sleep were higher in the group that received the Suanzaoren decoction. No adverse reactions were recorded in the study.